Aeterna Zentaris (AEZS) Competitors $3.14 +0.14 (+4.50%) As of 08/27/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsTrendsBuy This Stock AEZS vs. FNCH, CING, AYTU, GDTC, PMN, DARE, MBRX, CMMB, LSB, and XFORShould you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Finch Therapeutics Group (FNCH), Cingulate (CING), Aytu BioPharma (AYTU), CytoMed Therapeutics (GDTC), Promis Neurosciences (PMN), Dare Bioscience (DARE), Moleculin Biotech (MBRX), Chemomab Therapeutics (CMMB), LakeShore Biopharma (LSB), and X4 Pharmaceuticals (XFOR). These companies are all part of the "pharmaceutical products" industry. Aeterna Zentaris vs. Its Competitors Finch Therapeutics Group Cingulate Aytu BioPharma CytoMed Therapeutics Promis Neurosciences Dare Bioscience Moleculin Biotech Chemomab Therapeutics LakeShore Biopharma X4 Pharmaceuticals Finch Therapeutics Group (NASDAQ:FNCH) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends. Which has higher valuation and earnings, FNCH or AEZS? Aeterna Zentaris has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFinch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.47Aeterna Zentaris$2.37M2.37-$16.55M-$14.86-0.21 Which has more volatility & risk, FNCH or AEZS? Finch Therapeutics Group has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Is FNCH or AEZS more profitable? Finch Therapeutics Group has a net margin of 0.00% compared to Aeterna Zentaris' net margin of -760.32%. Finch Therapeutics Group's return on equity of -69.14% beat Aeterna Zentaris' return on equity.Company Net Margins Return on Equity Return on Assets Finch Therapeutics GroupN/A -69.14% -26.92% Aeterna Zentaris -760.32%-83.45%-45.76% Does the media favor FNCH or AEZS? In the previous week, Finch Therapeutics Group had 1 more articles in the media than Aeterna Zentaris. MarketBeat recorded 1 mentions for Finch Therapeutics Group and 0 mentions for Aeterna Zentaris. Finch Therapeutics Group's average media sentiment score of 0.00 equaled Aeterna Zentaris'average media sentiment score. Company Overall Sentiment Finch Therapeutics Group Neutral Aeterna Zentaris Neutral Do insiders & institutionals hold more shares of FNCH or AEZS? 21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 0.7% of Aeterna Zentaris shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Comparatively, 0.1% of Aeterna Zentaris shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryFinch Therapeutics Group beats Aeterna Zentaris on 7 of the 11 factors compared between the two stocks. Get Aeterna Zentaris News Delivered to You Automatically Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AEZS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AEZS vs. The Competition Export to ExcelMetricAeterna ZentarisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.62M$848.51M$5.78B$9.79BDividend YieldN/A4.84%3.95%4.02%P/E Ratio-0.211.1331.2426.59Price / Sales2.3726.55429.49156.00Price / CashN/A19.5637.7359.36Price / Book0.216.7310.366.68Net Income-$16.55M-$4.20M$3.27B$265.59M7 Day Performance16.11%16.11%1.40%0.62%1 Month Performance-19.62%17.10%6.21%2.61%1 Year Performance-17.28%34.92%46.60%22.34% Aeterna Zentaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AEZSAeterna ZentarisN/A$3.14+4.5%N/A-17.3%$5.62M$2.37M-0.2120Gap UpHigh Trading VolumeFNCHFinch Therapeutics Group0.3244 of 5 stars$12.50-1.6%N/A+1.6%$20.08MN/A-1.42190Gap DownHigh Trading VolumeCINGCingulate2.3899 of 5 stars$3.76-9.6%$26.00+591.5%-50.8%$19.78MN/A-0.4420Analyst RevisionAYTUAytu BioPharma3.7648 of 5 stars$2.20flat$10.00+354.5%-4.1%$19.75M$81.66M-3.06160Positive NewsGap UpGDTCCytoMed Therapeutics2.5668 of 5 stars$1.75-1.7%$5.00+185.7%+31.0%$19.15M$69.50K0.00N/ANews CoveragePositive NewsPMNPromis Neurosciences3.237 of 5 stars$0.57-8.4%$4.33+667.0%-60.8%$18.47MN/A-2.695Positive NewsDAREDare Bioscience2.5093 of 5 stars$2.02-4.3%$12.00+494.1%-40.3%$18.24M-$17.70K-0.9430MBRXMoleculin Biotech2.8423 of 5 stars$0.60-1.8%$4.00+571.0%-84.3%$18.05MN/A0.0020News CoverageAnalyst ForecastGap DownCMMBChemomab Therapeutics3.2487 of 5 stars$0.93-1.1%$8.50+814.0%-54.2%$17.54MN/A-1.5820News CoverageAnalyst ForecastGap UpLSBLakeShore Biopharma1.1758 of 5 stars$0.82flatN/A-81.9%$17.03M$85.67M0.00773News CoverageXFORX4 Pharmaceuticals4.0377 of 5 stars$2.93+17.7%$71.17+2,328.9%-80.1%$16.96M$32.77M-0.2080Gap UpHigh Trading Volume Related Companies and Tools Related Companies FNCH Alternatives CING Alternatives AYTU Alternatives GDTC Alternatives PMN Alternatives DARE Alternatives MBRX Alternatives CMMB Alternatives LSB Alternatives XFOR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AEZS) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeterna Zentaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access